Abstract
Data from pre-clinical and clinical studies provide evidence that colony-stimulating factors (CSFs) and other growth factors (GFs) can improve stroke outcome by reducing stroke damage through their anti-apoptotic and anti-inflammatory effects, and by promoting angiogenesis and neurogenesis. This review provides a critical and up-to-date literature review on CSF use in stroke. We searched for experimental and clinical studies on haemopoietic GFs such as granulocyte CSF, erythropoietin, granulocyte-macrophage colony-stimulating factor, stem cell factor (SCF), vascular endothelial GF, stromal cell-derived factor-1α and SCF in ischemic stroke. We also considered studies on insulin-like growth factor-1 and neurotrophins. Despite promising results from animal models, the lack of data in human beings hampers efficacy assessments of GFs on stroke outcome. We provide a comprehensive and critical view of the present knowledge about GFs and stroke, and an overview of ongoing and future prospects.
Original language | English |
---|---|
Pages (from-to) | 1645-1687 |
Number of pages | 43 |
Journal | Journal of Cellular and Molecular Medicine |
Volume | 15 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2011 |
Keywords
- EPO
- G-CSF
- GM-CSF
- Growth factors
- IGF-1
- SCF
- SDF-1α
- Stroke
- VEGF
ASJC Scopus subject areas
- Cell Biology
- Molecular Medicine